Esperion to Participate in The 2026 Citizens Life Sciences Conference

Rhea-AI Summary

Esperion (NASDAQ: ESPR) will participate in the 2026 Citizens Life Sciences Conference on March 11, 2026, presenting at 8:25 a.m. ET. The presentation will be webcast live and accessible via the company’s investor and media website. A replay will be available about two hours after the call and archived for approximately 90 days.

News Market Reaction

+0.56%

1 alert

+0.56% News Effect

On the day this news was published, ESPR gained 0.56%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference date: March 11, 2026 Presentation time: 8:25 a.m. ET Webcast replay delay: approximately two hours +1 more

4 metrics

Conference date March 11, 2026 Citizens Life Sciences Conference participation

Presentation time 8:25 a.m. ET Scheduled conference webcast start time

Webcast replay delay approximately two hours Delay before replay becomes available after call completion

Replay archive period approximately 90 days Duration replay will remain on company website

Market Reality Check

Price: $3.52 Vol: Volume 3,150,227 vs 20-da...

normal vol

$3.52 Last Close

Volume Volume 3,150,227 vs 20-day average 4,330,571 (relative volume 0.73). normal

Technical Trading above 200-day MA of 2.38 with price at 3.55.

Peers on Argus

ESPR up 3.5% while peers are mixed: AQST +6.02%, EOLS +0.92%, ORGO +0.81%, SIGA ...

ESPR up 3.5% while peers are mixed: AQST +6.02%, EOLS +0.92%, ORGO +0.81%, SIGA -0.15%, AKBA -0.83%, suggesting stock-specific factors rather than a broad sector move.

Historical Context

5 past events · Latest: Feb 17 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 17	Patent settlement	Positive	+3.5%	Settlement with Alkem limiting U.S. generics for NEXLETOL/NEXLIZET until 2040.
Feb 11	Equity inducement	Neutral	+2.1%	Grant of 40,200 RSUs to 11 new employees under inducement plan.
Jan 11	Business update	Positive	-8.5%	Preliminary 2025 results and long-term Vision 2040 growth strategy at JPM conference.
Jan 05	Conference participation	Positive	+2.7%	Announcement of presentation and fireside chat at J.P. Morgan Healthcare Conference.
Dec 19	Guideline inclusion	Positive	+3.4%	Bempedoic acid recommended in 2025 ACC statement for PAD with diabetes.

Pattern Detected

Recent news has generally seen positive price reactions, with one notable selloff on a business update despite strong preliminary figures.

Recent Company History

Over the past few months, Esperion has reported several notable developments, including a patent litigation settlement extending U.S. generic protection on NEXLETOL/NEXLIZET to 2040, inducement equity grants to new hires, and a major business update with preliminary 2025 revenue and expense guidance for 2026. Earlier, the company highlighted inclusion of bempedoic acid in an ACC scientific statement and participated in major healthcare conferences. Today’s conference-participation news fits this pattern of ongoing investor outreach and visibility efforts.

Market Pulse Summary

This announcement highlights Esperion’s upcoming presentation at a webcasted life sciences conferenc...

Analysis

This announcement highlights Esperion’s upcoming presentation at a webcasted life sciences conference on March 11, 2026, continuing a pattern of active investor outreach alongside prior participation in major healthcare meetings. In recent months, the company reported patent settlements extending protection on NEXLETOL/NEXLIZET and released detailed preliminary 2025 revenue and 2026 expense guidance. Investors may watch future events for added clarity on growth, profitability, and execution against the Vision 2040 strategy.

AI-generated analysis. Not financial advice.

ANN ARBOR, Mich., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2026 Citizens Life Sciences Conference on March 11, 2026, at 8:25 a.m. ET.

The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days.

About Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies. The Company leverages deep domain expertise in ACLY biology to develop and commercialize transformative medicines for patients worldwide. Esperion currently markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels and are at risk of cardiovascular disease.

With a broad U.S. commercial infrastructure and global approvals across more than 40 countries, Esperion is well positioned to serve as a partner-of-choice for global innovators seeking U.S. market access through acquisition, in-license, co-promotion and revenue share opportunities. In tandem, the Company is advancing its leadership in ACLY biology to build a diversified pipeline of novel product candidates, including treatments for Primary Sclerosing Cholangitis and renal diseases. For more information, visit esperion.com and follow Esperion on LinkedIn and X.

Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903

Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438

FAQ

When will Esperion (ESPR) present at the Citizens Life Sciences Conference on March 11, 2026?

Esperion (ESPR) will present at the Citizens Life Sciences Conference on March 11, 2026 at 8:25 a.m. ET. According to the company, the session is webcast live and viewers can access the presentation via the investor and media section of the company website.

How can investors watch the Esperion (ESPR) webcast for the March 11, 2026 presentation?

Investors can watch the Esperion (ESPR) webcast live on the company’s investor and media website. According to the company, the live stream is available at the scheduled time and will include links to the replay after the event.

When will the replay of Esperion's (ESPR) March 11, 2026 webcast be available?

The replay of Esperion's (ESPR) webcast will be available approximately two hours after the completion of the call. According to the company, the replay will be archived on the company website for roughly 90 days for on-demand viewing.

How long will Esperion's (ESPR) webcast replay remain archived after the March 11, 2026 conference?

Esperion (ESPR) will archive the webcast replay for approximately 90 days following the event. According to the company, investors can access the archived replay via the investor and media section of the company website during that period.

What time zone is used for Esperion's (ESPR) March 11, 2026 presentation start time?

The presentation start time for Esperion (ESPR) is listed in Eastern Time (ET) at 8:25 a.m. ET on March 11, 2026. According to the company, all public scheduling and webcast details reference Eastern Time for the event.

Where should media and investors go to access Esperion's (ESPR) Citizens Life Sciences Conference materials?

Media and investors should visit Esperion's (ESPR) investor and media website to access the live webcast and replay. According to the company, presentation materials and the replay link will be available through that site around the event date.